Project Grant R01HL182812
Award Date 6/1/26
Completion Date 2/29/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- Federal Grant Award Summary The Regents of the University of Minnesota received a $174,528 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2030. This award supports reverse translational research to identify novel treatment targets for atrial myopathy, a condition involving structural, mechanical, or electrophysiological changes in the atria that may...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a $719,882 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 20, 2025, with completion scheduled for May 31, 2030. The award supports research to elucidate lung-specific immune pathways driving post-hematopoietic cell transplantation (HCT) lung injury in pediatric patients. The research deliverables include...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,072,936 Project Grant to the University of California, San Diego under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 15, 2025, with completion targeted for June 30, 2029. This award funds research examining protein aggregation mechanisms in hematopoietic stem cells (HSCs) and their relationship to age-associated decline in blood and immune cell regeneration. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a Project Grant totaling $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) effective May 1, 2026, through January 31, 2030. This research project investigates the pathogenic role of a multipotent cardiac fibroblast population in heart failure, specifically focusing on how stem cell antigen-1 (SCA-1)-expressing cells that upregulate platelet-derived...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, San Diego a Project Grant of $1,427,011 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 15, 2025, with a completion date of May 31, 2030. The research project focuses on major histocompatibility complex (MHC) gene editing to prevent hematopoietic stem cell (HSCT) graft rejection. The award funds investigation of human leukocyte antigen (HLA)...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $151,092 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2030. This five-year research initiative focuses on investigating macrophage polarization and function in graft-versus-host disease (GVHD), a major complication of allogeneic hematopoietic stem cell transplantation...
- Federal Grant Award Summary New York University School of Medicine received a $1.65 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 25, 2025, with completion targeted for March 31, 2030. The grant funds research investigating HLA (Human Leukocyte Antigen) eplet mismatches (EMM) as a biomarker for immunologic risk in heart transplant recipients. The research aims to develop a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Colorado–Denver a Project Grant totaling $111,626 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025, through July 31, 2027. This research initiative focuses on investigating macrophage populations as a therapeutic target to attenuate pulmonary hypertension (PH) associated with sickle cell disease (SCD). The project will deliver...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of New Mexico Health Sciences Center a Project Grant of $586,637 (awarded September 1, 2025, with completion by August 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research on immune dysfunction in hypoxic pulmonary hypertension. The research project will investigate the mechanisms by which chronic hypoxia causes immune dysregulation...